IL-23 inhibitors
FDA Approves Guselkumab for UC
The FDA has approved guselkumab (Tremfya, Janssen) for patients with moderately to severely active ulcerative ...
SEPTEMBER 12, 2024
FDA Approves Risankizumab for Ulcerative Colitis
The FDA has approved risankizumab (Skyrizi, AbbVie) for patients with moderate to severe ulcerative colitis.
JUNE 27, 2024
Anti–IL-23 Agents Effective After Prior UC Treatment Failure
VANCOUVER, B.C.—Two different monoclonal antibodies targeting the interleukin-23 p19 subunit achieved all of ...
JANUARY 26, 2024
Advanced Therapies for IBD Do Not Appear To Raise Thrombotic Risk
In patients with IBD, neither biologics nor small molecule targeted therapies increase the risk for major adverse ...
DECEMBER 30, 2023
More Insight Into Anti-Interleukins
This month’s report focuses on the anti-interleukin treatments for inflammatory bowel disease, specifically ...
SEPTEMBER 21, 2023
Dual-Targeted Therapy in IBD Not Yet Ready for Prime Time
More evidence on the safety and efficacy of dual-targeted therapy for IBD is needed, according to presentations at ...
MARCH 22, 2023
